| Nicole Christine Steineke, MD | |
|
2050 Pfingsten Rd, Glenview, IL 60026-1324 | |
| (847) 657-1820 | |
| Not Available |
| Full Name | Nicole Christine Steineke |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 12 Years |
| Location | 2050 Pfingsten Rd, Glenview, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356699987 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 125.061938 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Alexian Brothers Home Health | Hanover park, IL | Home health agency |
| St Alexius Medical Center | Hoffman estates, IL | Hospital |
| Alexian Brothers Medical Center 1 | Elk grove village, IL | Hospital |
| Northwest Community Hospital 1 | Arlington heights, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bonaventure Medical Foundation Llc | 7517863178 | 153 |
News Archive
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $21.0 million of shares of its Series 7 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to four institutional investors.
Republicans were successful in blocking a "slimmed-down package of jobless benefits and state aid late Thursday" as Sens. Ben Nelson, D-Neb., and Joseph Lieberman, I-Conn., voted with them, The Washington Post reports.
Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
New results from a prospective clinical trial conducted in France show that children with low-risk retinoblastoma do not need postoperative (adjuvant) chemotherapy to prevent disease recurrence or metastasis; the results also suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment, or perhaps forego it altogether. Avoiding chemotherapy spares patients from treatment side effects and long-term health risks, such as cardiovascular disease and development of a second cancer.
› Verified 8 days ago
| Entity Name | Bonaventure Medical Foundation Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588775647 PECOS PAC ID: 7517863178 Enrollment ID: O20031212000374 |
News Archive
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $21.0 million of shares of its Series 7 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to four institutional investors.
Republicans were successful in blocking a "slimmed-down package of jobless benefits and state aid late Thursday" as Sens. Ben Nelson, D-Neb., and Joseph Lieberman, I-Conn., voted with them, The Washington Post reports.
Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
New results from a prospective clinical trial conducted in France show that children with low-risk retinoblastoma do not need postoperative (adjuvant) chemotherapy to prevent disease recurrence or metastasis; the results also suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment, or perhaps forego it altogether. Avoiding chemotherapy spares patients from treatment side effects and long-term health risks, such as cardiovascular disease and development of a second cancer.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicole Christine Steineke, MD 765 Jody Ln, Hoffman Estates, IL 60169-2709 Ph: (847) 942-6800 | Nicole Christine Steineke, MD 2050 Pfingsten Rd, Glenview, IL 60026-1324 Ph: (847) 657-1820 |
News Archive
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $21.0 million of shares of its Series 7 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to four institutional investors.
Republicans were successful in blocking a "slimmed-down package of jobless benefits and state aid late Thursday" as Sens. Ben Nelson, D-Neb., and Joseph Lieberman, I-Conn., voted with them, The Washington Post reports.
Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
New results from a prospective clinical trial conducted in France show that children with low-risk retinoblastoma do not need postoperative (adjuvant) chemotherapy to prevent disease recurrence or metastasis; the results also suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment, or perhaps forego it altogether. Avoiding chemotherapy spares patients from treatment side effects and long-term health risks, such as cardiovascular disease and development of a second cancer.
› Verified 8 days ago
Martin Kovachevich, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2050 Pfingsten Rd, Suite 330, Glenview, IL 60026 Phone: 847-998-4100 Fax: 847-998-8439 | |
Leslie Mendoza Temple, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Chestnut Ave, Suite A, Glenview, IL 60026 Phone: 847-657-3540 Fax: 847-657-3521 | |
Dr. Deborah Elizabeth Miller, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2050 Pfingsten Rd Ste 200, Glenview, IL 60026 Phone: 847-657-1820 Fax: 847-657-1823 | |
Khaldoun Dalbik, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2050 Pfingsten Rd, Glenview, IL 60026 Phone: 847-657-1810 | |
Dr. Ezechinyerem D Uzosike, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2050 Pfingsten Rd, Suite 200, Glenview, IL 60026 Phone: 847-657-1840 Fax: 847-657-1823 | |
Rachael Libertin, Family Medicine Medicare: Medicare Enrolled Practice Location: 2050 Pfingsten Rd, Glenview, IL 60026 Phone: 847-657-1812 | |
Esther Francine Vergara, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1255 Milwaukee Ave, Glenview, IL 60025 Phone: 847-294-5490 Fax: 847-294-5496 |